A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study To Assess Efficacy And Safety Of SER-287 In Adults With Active Mild-To-Moderate Ulcerative Colitis
Research Start Date
Status
Active
The primary objective of this study is to demonstrate the efficacy of SER-287, after ten (10) weeks of induction dosing (following vancomycin pre-treatment), in achieving clinical remission.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.